Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
488 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | terminated | Phase 2 | 17 | Beth Israel Medical CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | terminated | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | terminated | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT00864513 | Study of Pemetrexed for Second-Line Pancreas Cancer | terminated | Phase 2 | 17 | Georgetown UniversityOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT01227018 | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer | terminated | Phase 2 | 15 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 23, 2014 | clinicaltrials |
| NCT01096732 | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)(HIPPoS) | terminated | Phase 2 | 3 | Lisa BaxOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00613730 | Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint(APPRISE 1) | terminated | Phase 2 | 3 | AmgenINDUSTRY | 0 | Jan 6, 2014 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00307723 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 52 | Massachusetts General HospitalOTHER | 0 | Aug 10, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Mar 15, 2019source: clinicaltrials